Can antitumor immunity help to explain "Oncogene addiction" ?

Cancer Cell

Volumn 18, Issue 5, 2010, Pages 403-405

  Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CRIZOTINIB; ERLOTINIB; GEFITINIB; IMATINIB; PLX 4032; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CELL; CELL DEATH; CHRONIC MYELOID LEUKEMIA; GASTROINTESTINAL TUMOR; GENE MUTATION; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR THERAPY; NEOPLASM; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 78249239770     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.11.002     Document Type: Short Survey

References (10)

1. Felsher D.W. Cancer Res. 2008, 68:3081-3086.
2. Felsher D.W., Bishop J.M. Mol. Cell 1999, 4:199-207.
3. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. N. Engl. J. Med. 2010, 363:809-819.
4. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Nat. Rev. Immunol. 2006, 6:383-393.
5. Gidekel S., Pizov G., Bergman Y., Pikarsky E. Cancer Cell 2003, 4:361-370.
6. Kaelin W.G. Nat. Rev. Cancer 2005, 5:689-698.
7. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., Ou S.H., Dezube B.J., Jänne P.A., Costa D.B., et al. N. Engl. J. Med. 2010, 363:1693-1703.
8. Muranski P., Restifo N.P. Curr. Opin. Immunol. 2009, 21:200-208.
9. Rakhra K., Bachireddy P., Zabuawala T., Zeiser R., Xu L., Kopelman A., Fan A.C., Yang Q., Braunstein L., Crosby E., et al. Cancer Cell 2010, 18:485-498. this issue.
10. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Nat. Rev. Immunol. 2008, 8:59-73.